Biodesix (BDSX) Receivables (2019 - 2026)

Biodesix (BDSX) has reported Receivables for 8 consecutive years, with $9.5 million the latest figure, recorded in Q1 2026.

• Receivables for Q1 2026 came in at $9.5 million, up 24.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.5 million (up 24.36% YoY), and the FY2025 annual result was $9.0 million, up 5.03% from the prior year.
• Receivables was $9.5 million for Q1 2026 at Biodesix, up from $9.0 million in the prior quarter.
• Over five years, Receivables peaked at $12.7 million in Q3 2025 and troughed at $3.8 million in Q1 2022.
• Average Receivables over 5 years is $7.3 million, with a median of $7.6 million recorded in 2025.
• Year-over-year, Receivables slumped 79.45% in 2022 and jumped 145.88% in 2024.
• Over 5 years, Receivables stood at $5.1 million in 2022, then surged by 51.61% to $7.7 million in 2023, then climbed by 12.03% to $8.6 million in 2024, then grew by 5.03% to $9.0 million in 2025, then increased by 5.14% to $9.5 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $9.5 million in Q1 2026, $9.0 million in Q4 2025, and $12.7 million in Q3 2025.